Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Notes underwriting agrmnt
Adamis Pharmaceuticals Corp (ADMP) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/15/2021 GN Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model
02/22/2021 GN Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
02/17/2021 GN Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate
01/29/2021 GN Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
01/28/2021 GN Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients
01/26/2021 GN Adamis Pharmaceuticals Provides Update On Its US Compounding Business
01/21/2021 GN SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
01/20/2021 GN Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
11/16/2020 GN Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI
11/09/2020 GN Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
11/05/2020 GN Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business Update
09/18/2020 GN Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
09/17/2020 GN Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
09/03/2020 GN Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
08/21/2020 GN Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
08/17/2020 GN Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
08/14/2020 GN Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19
08/05/2020 GN Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
07/01/2020 GN Adamis Pharmaceuticals Provides Update on SYMJEPI Products
06/15/2020 GN Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19
05/18/2020 GN Adamis Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update
05/18/2020 GN Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA
05/15/2020 GN Adamis Pharmaceuticals Schedules First Quarter 2020 Earnings Conference Call and Business Update
05/11/2020 GN Adamis Pharmaceuticals Provides Update on SYMJEPI Products and Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI Products
04/23/2020 GN Adamis Pharmaceuticals Announces Publication Demonstrating PET Scan Results of Higher Dose Naloxone in Monkeys
04/21/2020 GN Adamis Pharmaceuticals Announces Production of Additional Drugs by its US Compounding Subsidiary to Aid in the COVID-19 Pandemic
04/15/2020 GN Adamis Pharmaceuticals Announces Receipt of Loan Proceeds Under Paycheck Protection Program
04/01/2020 GN Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic
03/30/2020 GN Adamis Pharmaceuticals Announces 2019 Financial Results and Business Update
02/21/2020 GN Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct Offering
02/19/2020 GN Adamis Pharmaceuticals Provides Update Regarding ZIMHI
12/19/2019 GN Adamis Pharmaceuticals Provides an Update on ZIMHI
11/18/2019 GN Adamis Pharmaceuticals Announces Publication of Comparative Pharmacokinetics of Community Use Naloxone Formulations
11/12/2019 GN Adamis Pharmaceuticals Announces Third Quarter 2019 Financial Results and Business Update
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy